Mast Cells: Molecular And Cell Biology

M Castells

Citation

Abstract

Corresponding Author:

Mariana Castells, M.D., Ph.D.

Asst. Professor, Harvard Medical School

44 Binney Street

DFCI SMith Bldg, Room 626-D

Boston, MA 02115

INTRODUCTION

Mast cells are important effector cells providing granule and membrane mediators as well as cytokines in allergic and inflammatory diseases. The study of surface molecules such as immunoglobulin receptors and adhesion molecules have greatly expanded our understanding of mast cell physiology. Activatory and inhibitory receptors have been defined with critical roles in maintaining cell functional activity. An active role for mast cells in antigen presentation to T cells has recently been shown, and direct interaction between mast cells and B cells providing signals for specific IgE production has been demonstrated. Functional receptors other than the high affinity IgE (FceRI) have been implicated in the anaphylactic response of IgE-deficient mice, suggesting that IgG receptors present in mast cells can be involved in immediate hypersensitivity reactions. A protective role for mast cells has recently been established through the release of TNF alpha in acute septic peritonitis .

Although metachromatic mast cells are easily recognized in peripheral tissues, little is known about the phenotype of mast cell precursors, their fate from the bone marrow to the tissues, the migration and homing processes and the factors and adhesion molecules that affect those processes. This review will describe recent advances in mouse and human mast cell biology and ontogeny.

MAST CELL ONTOGENY AND DEVELOPMENT

1. ROLE OF C-KIT PROTOONCOGENE AND STEM CELL FACTOR (SCF)

Mutant mice of the W/W and Sl/Sl phenotypes lack mature mast cells and exhibit hypoplastic anemia, hypopigmentation and sterility ([1],[2]). The W locus encodes the c-kit protooncogene, a member of the immunoglobulin superfamily within the receptor tyrosine kinase family ([3]). The Sl locus codes for the ligand of c-kit, also called stem cell factor (SCF) or kit-ligand (KL) ([4]). Kitamura and coworkers have shown that bone marrow transplantation from +/+ normal mice or Sl/Sld mutant mice cured the mast cell deficiency in the W/Wv deficient mice, reflecting a hematopoietic defect in the mast cell lineage (2). The deficiency in the Sl mutants could not be cured with bone marrow transplantation, indicating that the defect was in the non-hematopoietic microenvironment ([5]). W and Sl mutations profoundly affect the mast cell lineage, indicating that c-kit and Stem Cell Factor (SCF) are crucial to the development of mast cells ([6]). The proliferation, differentiation, chemotaxis and secretory functions of mouse, rat and human mast cells are all affected by the interactions between c-kit and SCF ([7],[8], [9], [10], [11]).

Elegant in vivo studies by Galli and coworkers of non-human primates such as baboons and cynomolgus monkeys treated subcutaneously with recombinant human SCF (rhSCF) for 21 or 28 days have shown increased mast cell numbers in multiple organs ([12]). Mast cell hyperplasia varied considerably according to the different anatomical sites with a predominant pattern at spleen, bone marrow and lymph nodes. At 100:g/kg/day mastocytosis occurred at the site of injection, bone marrow, mesenteric lymph nodes, liver and spleen, a pattern similar to that seen in some patients with systemic mastocytosis ([13],[14]). When rhSCF was discontinued and the monkeys maintained for 15 days without it, the

numbers of mast cells declined and were undistinguishable from the control non-treated monkeys. Systemic expansion and contraction of the mast cell population occurred without any observed side effects. In vitro data suggests that SCF promotes mast cell survival by suppressing apoptosis ([15]).

Point mutations of the cytoplasmic tyrosine domain of the c-kit protooncogene receptor have shown a factor independent development of rat and mouse mast cells. The mouse P815 mast cell line and the rat RBL-2H3 line have an Asparagine substituted by a Tyrosine at amino acids 814 and 817 respectively ([16,17]). Both cell lines have been shown to have activated c-kit kinase and do not need SCF for growth and survival.

2.HUMAN MASTOCYTOSIS AND MAST CELL PRECURSORS

Increased numbers of mast cells are seen in human mastocytosis, which can be localized to the skin (as in solitary mastocytomas or urticaria pigmentosa lesions) or can involve various organs (bone marrow, bone, liver, spleen, lymph nodes) as seen in systemic mastocytosis (13). The phenotype of the hyperplastic mast cells is no different than that of the normal mast cells at the site of localization. The cause of human mastocytosis is still unclear but c-kit and SCF have been both implicated in the pathogenesis. Earlier studies on cutaneous mastocytosis (urticaria pigmentosa) have shown an excess of soluble SCF in lesional tissue sections by immunohistochemistry, in which the cellular source was not identified ([18]) . A post-translational defect with local increase in SCF in these patients was thought to be responsible for the reactive mast cell hyperplasia. In patients with systemic mastocytosis and associated myelodysplastic syndrome a point mutation has been identified in the catalytic domain of c-kit that causes an Asp816-Val substitution ([19]), which is also found in the HMC1 human mast cell leukemia line ([20]). This mutation is analogous to the ones found in the rat mast cell line RBL-2H3 and the mouse mast cell line P815 both of which induce ligand-independent mast cell growth and have tumorogenic potential. Recently the same Asp816-Val mutation has been found in patients with only urticaria pigmentosa and in patients with aggressive mastocytosis (type III) without hematologic malignancy ([21]). A new mutation has been established in the same tyrosine domain of c-kit with the substitution Asp820-Gly ([22]) in a patient with aggressive mastocytosis. Since the reported mutations occur in both benign and malignant forms of the disease other associated factors or mutations might be important for the development of aggressive or malignant mastocytosis .

Mast cells, although having their origin in the bone marrow and expressing hematopoietic surface markers, do not circulate in the blood as recognizable, mature cells ([23]). In humans, circulating precursor mast cells express the CD34 epitope and can be differentiated in vitro into metachromatic, tryptase positive mast cells under the influence of SCF ([24]). Cord blood as well as fetal liver mononuclear cells have also been shown to be a source of mast cell progenitors ([25,26]). However, the identity of the circulating progenitors has not been elucidated, and little is known about the differentiation pathways that lead to mature, tissue mast cells.

Phenotypic identification of immature mast cells has been hampered by the low frequency of those circulating cells and the lack of specific mast cell surface markers at the early stages of development. Systemic mastocytosis has provided an in vivo model for the study of mast cell early forms since increased number of circulating mast cell precursors is expected as a reflection of the increased number of mast cells in the tissues. The phenotype of circulating early mast cell forms is described in a patient with type III systemic mastocytosis in which no hematological malignancy was apparent, nor were mature mast cells present in the peripheral blood. An agranular non metachromatic mononuclear cell was identified at low frequency (1% to 3%) in the peripheral blood that expressed at least 3 granule proteins (tryptase, Carboxipeptidase A (CPA) and Cathepsin G) the surface marker c-kit and lacked chymase ([27]). The same mononuclear agranular tryptase, c-kit, CPA and Cathepsin G positive cell was present in the spleen and lymph nodes in association to hyperplastic mature mast cells. This circulating cell that lacks metachromasia but expresses tryptase and c-kit is a likely candidate for previously unrecognized mast cell circulating progenitors (Figure 1). Surface immunohistochemical staining for SCF was shown in these mononuclear mast cell progenitors, suggesting the possibility of an autocrine regulation of their proliferation and differentiation (Figure 2). A committed precursor for the mast cell lineaje in murine fetal blood has also been identified. The murine promastocyte expresses low levels of the membrane bound T cell antigen Thy1, high levels of c-kit, has mRNA for the mast cell granule proteases MMCP2, MMCP4 and CPA, lacks FceRI alpha chain and is weakly metachromatic ([28]). Its phenotype shares similarities with the precursor identified in the aggressive mastocytosis patient described above (27) indicating that non-

metachromatic mast cell precursors travel in the blood stream that can now be recognized with appropriate phenotypic characterization.

3.MAST CELL HETEROGENEITY

Morphology and metachromasia have been the two fundamental criteria for the recognition of tissue mast cells. The description of mast cells as mononuclear metachromatic cells needs to be amplified to include cells with multilobulated nuclei. Human mast cells can have segmented nuclei analogous to mouse mast cells which can possess multilobular nuclei at various tissue localizations ($_{29}$).Those multilobulated mast cells express the normal protease phenotype as well as c-kit and have an electron microscopy structure similar to mononuclear mast cells at the same tissue localization (29). Metachromasia is found in mature mast cell but precursor, immature, degranulated and atypical mast cells may demonstrate limited or no metachromasia while they express granule and membrane specific proteins (27).

Biochemical evidence of mast cell heterogeneity in humans is based on the presence of proteases, which are the bulk of the protein content of the granules. Although the initial studies by Schwartz at al. indicated the presence of only two distinct types of mast cells ($_{30}$), it is clear that there are at least three types of mature mast cells based on immunochemical studies. Mast cells containing only tryptase and named MCt predominate in the intestinal mucosal and alveoli and are scroll-rich; mast cells containing tryptase, chymase and carboxypeptidase and named MCtc predominate in skin and intestinal submucosa and have lattice-rich and amorphous granules (30); and the less frequent MCc only containing chymase is found in the intestinal submucosa and nasal mucosa ($_{31}$). Intestinal MCt are decreased in AIDS and severe immunodeficiencies while MCtc are unchanged in those diseases ($_{32}$). This indicates a CD4+ T cell dependency for the MCt. MCt from different tissues may represent a heterogeneous population itself, since several different tryptase transcripts have been isolated. Five highly homologous tryptase cDNAs (>92% overall identity) have been cloned from human lung mast cells (alpha and beta forms) and from human skin mast cells (I,II and III forms with a 98% identity with the beta form) with different N-linked glycosylation patterns ($_{33}$). Although both specific alpha and beta tryptase mRNAs are transcribed in tissue-derived mast cells, beta transcripts seem to predominate in skin and lung, and HMC-1 (human leukemic mast cell line) cells which have no detectable alpha

transcripts ($_{34}$). Expression of tryptases seems therefore tissue regulated and suggests a more complex heterogeneity pattern than reported. Tryptase purifed from lung and other human sources has been shown to cleave bronchodilator peptides (vasoactive intestinal polypeptide VIP, peptide histidine methionine and vasodilator calcitonin gene-related peptide), has mitogenic activity for fibroblasts and epithelial cells, activates collagenase from synovial cells, stimulates the release of IL-8 and upregulates the expression of ICAM-1 on epithelial cells ($_{35}$).

Mast cell heterogeneity is now being shown at the level of cytokine transcription and translation. Immunohistochemical and in situ RNA hybridization studies have looked at the distribution of IL-4, IL-5 and IL-6 proteins and mRNA in human skin, nasal and bronchial tissues. IL-4 is found preferentially in the MCtc subset, including skin with little IL-4 present in MCt (15%). IL-5 and IL-6 are restricted to the MCt subset ($_{36}$). These findings are consistent with a different profile of cytokine generation and release depending on mast cell localization and suggest specific biologic functions for the different mast cells subsets.

4. CYTOKINES IN MAST CELL DEVELOPMENT

Originally described by Kitamura, the reconstitution of mast cell-deficient mice with bone marrow cells or with bone marrow derived mast cells cultured with IL3 indicated that under the influence of tissue factors a common precursor could give rise to all types of mature differentiated mast cells ($_{37}$). Numerous cytokines have been identified that influence the in vitro expression of proteases in mouse mast cells ($_{38}$). A combination of IL-9 and SCF (c-kit ligand) will induce expression of all known mouse proteases as in the population of mature mast cells found in liver and spleen ($_{39}$). Human CD34 positive cells develop into an almost pure mast cell population in the presence of a combination of SCF and IL-6 ($_{40}$). These cultured human mast cells express functional high affinity IgE receptors (FceRI) and are predominantly of the MCt type containing only tryptase, with a minority (30%) being of the MCtc type containing tryptase and chymase ($_{41}$). Mast cells in turn produce and store cytokines. Murine mast cells have been shown to produce among other cytokines IL-1 beta, IL-6 and TNF alpha which is a potent preformed proinflammatory cytokine found also in human mast cells ($_{42}$). The elegant experiments of Malviya et al. and Echtenacher et al. have shown a protective role for mast cells in acute bacterial peritonitis that is blocked by anti-TNF alpha antibodies ($_{43,44}$). In Maleviya experiments W/Wv mast cells deficient mice were

20 fold less efficient that wild type or reconstituted mice in clearing enterobacteria when injected into the peritoneal cavity. TNF alpha from mouse mast cells was found essential for the clearence of Klebsiella Pneumoniae in a peritonitis model (44).

MIGRATION OF MAST CELL

Epithelial migration of mast cells has been suggested in vivo by the observations of Enerback et al. (45). Patients with allergic rhinitis before the pollen season were found to have mast cells in the connective tissue of the nasal mucosa with a redistribution occuring during the pollen season. An increased number of mast cells in the epithelium in close contact with the surface of the nose was seen but the total number of mast cells was not changed indicating an allergen induced mast cell migration. Data from mice infected with Trichinella Spiralis has confirmed that mast cells sequentially express different proteases as they progressively appear in the submucosa , lamina propria and epithelium mucosa at the height of the infection (46). In the recovery of the disease mast cell migrate to the villi and submucosa and alter their protease phenotype to accommodate to the tissue specific phenotype. It is clear that mast cell can reversibly alter their granule phenotype but no studies are available to identify which surface membrane structures are directly involved in the migration process and what soluble or cell bound ligands direct and orquestrate it.

1. ADHESION MOLECULES

Mast cell phenotypes are influenced by tissue factors that affect not only the expression of granule proteases and membrane mediators but also the expression of surface molecules. Surface and cell adhesion molecules that mediate mast cell attachment to extracellular matrix proteins (ECM) and to other tissue resident cells are important factors during mast cell differentiation, migration and homing (47).

In the connective tissue mast cells interact with the extracellular matrix proteins such as fibronectin, laminin and vitronectin and resident cells such as fibroblasts. The adherence of mast cells to fibroblasts is in part mediated by the interaction of fibroblast membrane-bound SCF with the c-kit receptor on mast cells (48). Mast cells adhere spontaneously to vitronectin (49), but need activation with PMA or FceRI crosslinking to adhere to fibronectin (50) and laminin (51). The adhesion to fibronectin is in part regulated by SCF, since it promotes adhesion of bone marrow-derived mast cells cultured in IL-3 to fibronectin in a dose-response fashion and at concentrations in the range of the plasma concentration of SCF (48). This interaction is RGD-peptide dependent, indicating that alpha 4 beta 1 and/or alpha 4 beta 7 integrins on mast cells are presumably the ligands for fibronectin. Expression of alpha 4, beta 1 and beta 7 genes has been shown in murine mast cells, and monoclonal antibodies have mapped the alpha 4, beta 1 and beta 7 proteins to the surface membrane (52). Engagement of matrix components and mast cell adhesion ligands can induce cell motility, intracellular proteins phosphorylation (53) and histamine and cytokine (TNF alpha) release (54). For example, FceRI-mediated activation of RBL-2H3 cells is enhanced by adhesion of cells to fibronectin-coated surfaces (55). The transcription of integrin genes is modulated during mast cell differentiation such that beta 1 and beta 7, but not alpha 4, transcripts are expressed in CTMC (56). The integrin complexes synthesized by mast cells are modulated by different cytokines. BMMC grown in SCF alone transcribe alpha 4, but not beta 7 integrins and BMMC grown in IL-3 induce beta 7 but abrogate alpha 4 transcription (56). A novel integrin chain, alpha M290, is expressed by mouse BMMC and is the human homolog of alpha E integrin which is known to pair with the beta 7 chain in intraepithelial lymphocytes (IEL) (57). The alpha e beta 7 pair was found to be un unexpected new ligand for E cadherin, which mediates homotypic adhesion, and may have a role in the homing process of IEL cells (58,59). Mouse alpha M290 integrin expression is inducible by TGF beta and IgE mediated crosslinking. Supernatants from activated mast cells expressing surface alpha M290 induce the paracrine expression of alpha M290 on other cells (57). This indicates that soluble mast cell products are capable of modifying the surface expression of integrins on other cells, influencing their cell-cell or cell-ECM interactions. Recent data has shown that metachromatic tryptase-positive mast cells derived from human fetal liver in the presence of rSCF adhere spontaneously to vitronectin through alpha V beta 3 surface integrins (60).

IMMUNOGLOBULIN SUPERFAMILY ACTIVATORY RECEPTORS FCERI AND FCGRIII

The activation of mast cell can be initiated by the aggregation of FceRI by IgE and antigen but aggregated IgG is also able to activate mast cells as well (61). The nature of the FcgR receptors present on the surface membrane of mouse mast cells has been described recently and their in vivo functions are now starting to be apparent. Three distinct low affinity IgG Receptors FcgRIIb1, FcgRIIb2, and

FcgRIII are expressed by mouse mast cells and found to be specific for IgG1, IgG2a and IgG2b with no cross reactivity with IgE. FcgRIII is composed of three chains, one alpha and two gamma, but the FcgRIIb1/b2 are single chain molecules ($_{62}$). FceRI and FcgRIII have a similar alpha chain which contains 2 immunoglobulin C2 extracellular domains,the FceRI has a beta chain lacking in the FcgRIII and both have two associated gamma chains with ITAM motifs (Immunoreceptor Tyrosine Based Activation Motifs) (Figure 3). The associated g chains function is to couple the receptors to signaling pathways ($_{63}$). The ITAM motifs have a central tyrosine that becomes phosphorylated by scr kinases when the receptors are clustered and propagate the downstream signals by recruitment of specific substrates leading to the release of membrane and granule mediators (63). The expression of FceRI on mast cells seems to be partly regulated by IgE since IgE deficient mice have little expression of FceRI as compared to normal littermates. The expression of FceRI in mast cell deficient mice and normal littermates can be greatly enhanced by treatment with IgE ($_{64}$). This upregulation is functionally significant since it increases substantially mediator and cytokine release (60% for serotonin and 6% for IL-6) upon IgE activation.

Mouse BMMC IL-3 express FcgIIb1 and b2 but little FcgRIII, whereas serosal mature mast cells (SMC) taken in vivo from the peritoneal cavity express primarily FcgRIII and some FcgRIIb1 ($_{65}$). Crosslinking the FcgRs induces secretory granule mediator (beta-hexosaminidase) and membrane generated arachidonic acid metabolites (LTC4 and PGD2) release from SMC at similar levels to those obtained when crosslinking the FceRI ($_{66}$). Transfection studies in rat basophil leukemia (RBL) cells expressing surface FcgRII and FcgRIII have shown that only the FcgRIII expressing transfectants release serotonin, LTC4 and TNF alpha ($_{67}$). Furthermore, these responses are dependent on the cytoplasmic sequence of the g chain containing the ITAM ($_{68}$). During mast cell ontogeny, both FceRI and FcgRs are expressed prior to granulation ($_{69}$). The functional relevance of the FcgRs on mast cells may be inferred from the in vivo anaphylactic response in IgE-deficient mice. Those mice produce no measurable IgE but normal levels of IgG and upon sensitization and antigen challenge present anaphylactic features with histological evidence of tissue mast cell degranulation and systemic histamine release ($_{70}$). This is consistent with IgG and FcgR activation of mast cells and mediator release such as that seen with cultured mast cells. FcgRIII receptors on mast cells play a significant role in the cutaneous Arthus reaction since mast cell deficient mice W/Wv when reconstituted in the skin with mast cells lacking FcgRIII had an attenuated response to immune complex mediated injury ($_{71}$).

INHIBITORY RECEPTORS
1.FCGRII

In vitro c-kit + committed mouse bone marrow derived mast cell progenitors lacking metachromatic granules express FcgRIIb1 and FcgRIIb2 ($_{72}$). Those receptors have been found to have endocytic capabilities but recent data suggest an important role as inhibitory receptors when crosslinked to the FceRI. When FcgRII receptors are transfected into RBL rat mast cells and crosslinked to the FceRI, IgE induced serotonin release is inhibited ($_{73}$). The inhibition is reversible upon disengagement of the FcgRII receptors and depends on an intact intracellular sequence common to FcgRIIb1 and b2 which contains a central motif, the ITIM (Immunoreceptor Tyrosine based Inhibitory Motif) (Figure 4). This motif is shared by other inhibitory receptors of the immune system including the KIRs (Killing Inhibitory Receptors) present on NK cells and CTLA-4 on T lymphocytes . The ITIM motifs become phosphorylated in the central tyrosine by specific src family kinases and recruit signaling molecules with inhibitory function ($_{74}$). Physiological stimulus that could crosslink both FceRI and FcgRII include antigen aggregated with IgG during immunotherapy treatment, in which patients raise high titers of IgG against immunizing antigens. FceRI mast cell activation can be controlled by the low affinity FcgRII when both receptors are clustered by the same stimulus.

2. THE GP49 FAMILY

A new immunoglobulin subfamily that is preferentially expressed on mouse mast cells and mononuclear macrophages, the gp49 family ($_{75}$), has been characterized which has novel regulatory functions for mast cells. Three of the members have been cloned -- gp49A, gp49B1 and gp49B2 -- and two genes isolated. The A gene codes for gp49A and the B gene for gp49B1 and gp49B2 by alternate splicing ($_{76}$). gp49A and gp49B1 are integral type I membrane glycoproteins, and gp49B2 is a secretory form, identical to gp49B1 but lacking the transmembrane domain. The extracellular domain of gp49 glycoproteins contains two C2 domains as in ICAM-2 , FcgRIII and FceRI alpha chains ($_{77}$). A newly recognized subfamily that includes gp49B1, the human myeloid receptor for IgA, the bovine myeloid Fc receptor for IgG2 and the KIRs expressed on NK cells and on T cell subsets has emerged based on the amino acid

sequence homology ($_{78}$) . The cytoplasmic domain of gp49B1 contains two ITIM motifs common to the FcgRII and KIRs. Coligation of gp49B1 with the FceRI on BMMC inhibited exocytosis in a dose related manner, including release of preformed mediators (b-hexosaminidase) and of newly generated lipid membrane derived (LTC4) ($_{79}$). Gp49B1 has been recently found to be expressed in NK cells and when substituting the cytoplasmic domain of a KIR by the cytoplasmic domain of gp49B1, the NK cell is able to deliver inhibitory signals when engaged by its MHC class I ligand to a greater extent than when expressing its own cytoplasmic domain ($_{80}$). Human counterparts for the mouse gp49 family have been cloned some of which have ITIM motifs in their cytoplasmic tail suggesting inhibitory functions such a seen with mouse gp49B1 ($_{81}$).

3. MHC CLASS II AND ANTIGEN PRESENTATION

Mast cells are found in close vicinity to intraepithelial (IEL) T lymphocytes, suggesting bi-directional influences through soluble factors or direct cell-cell interactions. Mouse bone marrow derived mast cells (BMMC) cultured in vitro in Concanavalin A conditioned medium and in the presence of interferon gamma can express MHC class II antigens required for antigen presenting cells (APC) to generate a T helper response (Th) ($_{82}$). The expression of MHC class II by mast cells is upregulated upon stimulation with lipopolysaccharide (LPS) and downregulated by exposure to IL-3. T helper hybridoma cells can be stimulated to proliferate and to produce IL-2 by mast cells expressing MHC Class II in the presence of antigen to a similar extent as when stimulated by B lymphoma cells (positive control APC). Anti-MHC class II monoclonal antibodies can block the interaction, which is limited to a subset of hybridomas, suggesting that mast cells may generate a narrower peptide repertoire as compared with B cells. Cognate interactions between Th cells and mast cells bearing processed antigen may therefore occur upon appropriate environmental stimulation of mast cells to induce expression of MHC class II. Whether other accessory molecules are involved in this interaction and what are the requirements for antigen processing and peptide presentation by mast cells have not been defined. A recent report has shown that rat serosal mast cells express accessory molecules for antigen presentation indicating that in vivo mast cells could process antigen and specifically activate Th cells ($_{83}$).

4. CD40 LIGAND (CD40L) AND IGE SYNTHESIS

The expression of IgE is controlled by switch recombination events leading to the translation of e heavy-chains and the differentiation and survival of IgE-committed B cells. The two signals required to direct recombination to the constant region of e heavy chains are the presence of cytokines such as IL-4 and IL-13 and the direct interaction between CD40 on B cells and CD40 ligand (CD40-L) ($_{84}$). Classically T cells have been described as the source of IL-4 and shown to stimulate B cells through CD40-L ($_{85}$). Purified human skin and lung mast cells, the basophilic cell line KU812 and human leukemic HMC-1 mast cell line express CD40L by indirect immunofluorescence which can be upregulated by PMA and ionomycin in HMC-1 cells ([86]). HMC-1 and KU812 cells induce the synthesis of IgE from purified tonsilar B cells after culture in the presence of IL-4 for 12 days in similar amounts to that obtained by T cell help. Highly purified lung mast cells stimulated with SCF were also found to support IgE production by B cells (86). This study indicates that mast cells at sites of allergic inflammation such as skin, lung and gut could potentially provide direct stimulation to B cells to induce and/or increase the local production of specific IgE. Whether activation of resident tissue mast cells is required for sufficient expression of the CD40-L and whether the same mast cells can provide IL-4 or IL-13 to support the switch recombination event has not been addressed.

SUMMARY

As shown in this review, the study of mast cells is complex and challenging. Human and mouse mast cell precursors travel in the blood stream that can be phenotipically recognized. Although hematopoietic in nature, mast cells become permanent residents once located in the tissues and have complex interactions with the environment. Autocrine and paracrine functions of mast cells have been described, and modulation of their phenotype and functions occurs through soluble factors as well as cell bound receptors and adhesion molecules. The discovery of at least two inhibitory pathways and receptors (FcgRII and gp49B1) strongly suggests that mast cell homeostasis is maintained through the balance between activatory and inhibitory stimuli. Therapeutic approaches may be designed that can take advantage of the naturally occuring pathways for mast cell inhibition.

References

1. Kitamura Y, Go S. Decreased production of mast cells in S1/S1d anemic mice. Blood 43:492, 1978.
2. Kitamura Y, Go S, Hatanaka S. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52:447-452, 1978.

3. Chabot B, Stephenson DA, Chapman VM, Besner P, Bernstein A. The protooncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335:88-89, 1988.

4. Huang E, Nocka K, Beier DR, Chu T-Y, Buck H, Lahm H-W, Wellner D, Leder P, Besner P. The hematopoietic growth factor KL is encoded by the S1 locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63:225, 1990.

5. Jarboe DL, Huff TF. W/Wv mice do not make mast cell-committed progenitors and SI/SId fibroblasts do not support development of normal mast cell-committed progenitors. J Immunol 142:2418-2423, 1989.

6. Galli SJ, Tsai M, Wershil BK at al. The effects of Stem cell factor, the ligand for c-kit receptor, on mouse and human mast cell development, survival and function. In: Biological and molecular aspects of mast cell and basophil differentiation and function. Kitamura et al. (eds). New York: Raven Press, Ltd. 1995, p.1-11.

7. Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol 142:965-974, 1993.

8. Nocka K, Buck J, Levi E, Besmer P. Candidate ligand for the c-kit transmembrane kinase receptor KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO J 10:3287-3294, 1990.

9. Nilsson G, Butterfield JH, Nilsson K, Siegbahn A. Stem cell factor is a chemotactic factor for human mast cells. J Immunol 153:3717-3723, 1994.

10. Columbo M, Horowitz EM, Botana LM, MacGlashan DW Jr, Bochner BS, Gillis S, Zsebo KM, Galli SJ, Lichtenstein LM. The recombinant human c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol 149:599-608, 1992.

11. Tsai M, Shih L-S, Newlands GFJ, Takeishi T, Langley KE, Zsebo KM, Miller HRP, Geissler EN, Galli SJ. The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomical distribution, histochemistry, and protease phenotype. J Exp Med. 174:125-131, 1991.

12. Galli SJ, Iemura A, Garlick DS, Ganba-Vitalo C, Zsebo KM, Andrews RG. Reversible expansion of primate mast cell populations in vivo by stem cell factor. J Clin Invest 91:148-152, 1993.

13. Travis WD, Li CY, Bergstraih EJ, Yam LT, Swee RG. Systemic mast cell disease: analysis of 58 cases and literature review. Medicine 67:345-368, 1988.

14. Metcalfe DD. The liver, spleen, and lymph nodes in mastocytosis. J Invest Dermatol 96:45S-46S, 1991.

15. Iemura A, Tsai M, Ando A, Wershil BK, Galli SJ. The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol 144:321-328, 1994.

16. Tsujimura T, Furitsu T, Morimoto M, et al. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 83:2619-26.

17. Kitamura Y, Tsujimura T, Jippo T, Kasugai T, Kanakura Y. Development of mast cells and basophils: Role of c-kit receptor tyrosine kinase for development, survival and neoplastic transformation of mast cells. Biological and molecular aspects of mast cell and basophil differentiation and function. Kitamura et al. (eds.) New York: Raven press, Ltd. 1995, p.91-104.

18. Longley BJ Jr, Morganroth GS, Tyrrell L, et al. Altered metabolism of mast- cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 328:1302-7, 1993.

19. Nagata H, Worobec AS, Oii CK, Chowdhury BA, Tannenbaum S, Suzuki Y, MetcalfeDD. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients whohave mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92:1-5, 1995.

20. Furisu T, Tsujimura T, Tono T. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia line causing ligand independent activation of c-kit product. J Clin Invest 1993;92:1736-44.

21. Longley BJ et al. Somatic c-kit activating mutation in urticaria pigmentosaand aggressive mastocytosis: establishment of clonality in a human mast cellneoplasm, Nat Genet.12:312-314, 1996.

22. Pignon JM, Giraudier S, Duquesnoy P, Jouault H, Imbert M, Vainchenker W, Vernant JP, Tulliez M. A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 96(2):374-6, 1997.

23. Valent P, Spanblochl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, Strobl H, Geissler K, Bettelheim P, Lechner K. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 80:2237-2245, 1992.

24. Kirschenbaum AS, Goff JP, Kessler SW, Mican JM, Zsebo KM, Metcalfe DD. Effect of IL-3 and Stem Cell Factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 148:772-777, 1992.

25. Ishikaza T, Furitsu T, Mitsui H, Takei M, Koszloski MA, Irani A-MA, Scbwartz LB, Dvorak AM, Zsebo KM, Gillis S. Development of human mast cells from umbilical cord blood cells by human and murine c-kit ligand. FASEB J 6:A1403, 1992.

26. Irani AA, Craig SS, Nilsson G, Ishizaka T, Schwartz LB. Characterization of human mast cells developed in vitro from fetal liver cells co-cultured with murine 3T3 fibroblasts. Immunology 77:136-143, 1992.

27. Castells M, Friend D, Bunnell C, Austen KF. The presence of membrane- bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis. J Allergy Clin Immunol 98:831-40,1996.

28. Rodewald HR, Dessing M, Dvorak AM, Galli SJ. Identification of a committedprecursor for the mast cell lineaje. Science 217:818-22, 1996.

29. Gurish MF, Friend DS, Webster M, Ghildyal N, Nicodemus CF, Stevens R. Mouse mast cells that possess segmented multi-lobular nuclei. Blood 90:382-90,1997.

30. Irani AA, Schechter NM, Craig SS, Deblois G, Schwartz LB. Two types of mast cells that have distinct neutral protease composition. Proc Natl Acad SciUSA 83:4464-8, 1986.

31. Weidner N, Austen KF. Evidence for morphologic diversity of human mast cells. Lab Invest 1990;63:63-72.

32. Irani AA, Craig SS, DeBlois G, Elson CO, Schechter NM, Schwartz LB. Deficiency of the tryptase positive, chymase negative mast cell in gastrointestinal mucosa of patients with defective T lymphocyte function. J Immunol 138:4381-86,1987.

33. Human mast cell tryptase multiple cDNAs and genes reveal a multigene serine protease family. Proc Natl Acad Sci USA 87:3811, 1990.

34. Xia HZ, Kepley CL, Sakai K, Chelliah J, Irani AM, Schwartz LB. Quantitation of Tryptase, Chymase, FceRIa, and FceRI mRNAS in human mast cells and basophils by competitive reverse transcription-polymerase chain reaction.

J Immunol 154:5472-5480, 1995.

35. Schwartz LB. Structure and function of human mast cell tryptase. In Biological and Molecular Aspects of Mast Cell and Basophil Differentiation and Function. Ed. Y Kitamura, S Yamamoto, SJ Galli and MW Greaves. RavenPress Ltd NY p.161-172, 1995.

36. Bradding P, Okayama Y, Church MK, Holgate ST. Heterogeneity of human mast cells based on their cytokine content. J Immunol, 1995

37. Nakano T, Sonoda T, Hayashi C, Yamatodani A, Kanayama Y, Yamamura T, Asai H, Yonezawa T, Kitamura Y, Galli SJ. Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. J Exp Med 162:1025, 1985.

38. Gurish MF, Ghildyal N, McNeil HP, Austen KF, Gillis S, Stevens RL. Differential expression of secretory granule proteases in mouse mast cells exposed to interleukin 3 and c-kit ligand. J Exp Med 175:1003-1012, 1992.

39. Eklund KK, Ghildyal N, Austen KF, Stevens RL. Induction by IL-9 and suppression by IL-3 and IL-4 of the levels of chromosome 14-derived transcripts that encode late-expressed mouse mast cell proteases. J Immunol 151:4266-4273, 1993.

40. Nakahata T, Tanaka I, Muraoka K, et al. Synergy of stem cell factor and other cytokines in mast cell development. In: Biological and Molecular Aspects of Mast Cell and Basophil Differentiation and Function. Galli et al (eds.) New York: Raven Press, 1995;8-9

41. Saito H, Ebisawa M, Sakaguchi N, et al. Characterization of cord blood-derived human mast cells cultured in the presence of Steel factor and IL-6. In: Biological and Molecular Aspects of Mast Cell and Basophil Differentiation and Function. Galli et al. (eds.) New York: Raven Press, 1995, p.50.

42. Church MK, Levi-Schaffer F. The human mast cell. J Allergy Clin Immunol 99:155-160, 1997.

43. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearence at sites of infection through TNF-a. Nature381:77-80, 1996.

44. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381:75-77, 1996.

45. Enerback L, Pipkorn U, Granerus G. Intraepithelial Migration of nasal mucosal mast cells in hay fever. Int Archs Allergy Appl Immun 80:44-51, 1986.

46. Friend DS, Ghidyal N, Austen KF, Gurish MF, Matsumoto R, Stevens R. Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype. J Cell Biol 135:279-90, 1996.

47. Hamawy MM, Mergenhagen SE, Siraganian RP. Adhesion molecules as regulators of mast-cell and basophil function. Immunol Today 15:62-66, 1994.48. Kinashi T, Springer TA. Steel factor and c-kit regulate cell-matrix adhesion. Blood 83:1033-1038, 1994.

48. Bianchine PJ, Burd PR, Metcalfe DD. IL-3-dependent mast cells attach to plate-bound vitronectin. J Immunol 149:3665-3671, 1992.

49. Dastych J, Costa JJ, Thompson HL, Metcalfe DD. Mast cell adhesion to fibronectin. Immunology 99:478-484, 1991.

50. Thompson HL, Burbelo PD, Metcalfe DD. Regulation of adhesion to mouse bone marrow-derived mast cells to laminin. J Immunol 145:3425-3431, 1990.

51. Gurish MF, Bell AF, Smith TJ, Ducharme LA, Wang R-

K, Weis JH. Expression of murine beta7, alpha4, and beta1 integrin genes by rodent mast cells. J Immunol. 149:1964-1972, 1992.

52. Hamawy MH, Mergenhagen SE, Siraganian RP. Cell adherence to fibronectin and the aggregation of the high affinity immunoglobulin E receptor synergistically regulate tyrosine phosphorylation of 105-115-kDa proteins. J Biol Chem 268:5227-5233, 1993.

53. Ra C, Yasuda M, Kim Z, Saito H, Nakahata T, Yagita H, Okumura K. Fibronectin receptor (FNR) integrins on mast cells are involved in cellular activation. In: Biological and Molecular Aspects of Mast Cell and Basophil Differentiation and Function. Kitamura et al. (eds.) New York: Raven Press, 1995, p. 239-247.

54. Hamawy MH, Oliver C, Mergenhagen SE, Siraganan RP. Adherence of rat basophilic leukemia (RBL-2H3) cells to fibronectin-coated surfaces enhances secretion. J Immunol 149:615-621, 1992.

55. Ducharme LA, Weis JH. Modulation of integrin expression during mast cell differentiation. Eur J Immunol 22:2603-2607, 1992.

56. Smith TJ, Ducharme LA, Shaw SK, Parker CM, Brenner MB, Kilshaw PJ, Weis JH. Murine M290 integrin expression modulated by mast cell activation. Immunity 1:393-403, 1994.

57. Cepek KL, Parker CM, Maara JL, Brenner MB. Integrin "E&7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol 150:3459-3470, 1993.

58. Cepek KL, Shaw SK, Parker CM, Russell GJ, Morrow JS, Rimm DL, Brenner MB. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alphaEbeta7 integrin. Nature 372:190-193, 1994.

59. Shimizu Y, Irani AM, Brown EJ, Ashman LK, Schwartz LB. Human mast cells derived from fetal liver cells cultured with stem cell factor express a functional CD51/CD61 (alpha v beta 3) integrin. Blood 86:930-939, 1995.

60. Tigelaar RE, Vaz NM, Ovary Z. Immunoglobulin receptors on mouse mast cells.J Immunol 106:661, 1971.

61. Ravetch JV, Luster AD, Weinshank R, Kochan J, Pavlovec A, Portnoy DA, Hulmes J, Pan YE, Unkeless JC. Structural heterogeneity and functional domains of murine immunoglobulin G Fc receptors. Science 234:718, 1986.

62. Cambier JC. Antigen and fc Receptor Signaling. The awesome power of the Immunoreceptor Tyrosine-Based Activation Motif (ITAM). J Immunol 155:3281-85, 1995.

63. Yamagushi M et al. IgE enhances mouse mast cell FceRI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE- dependent reactions. J Exp Med 185:663-672, 1997.

64. Katz HR, Arm JP, Benson AC, Austen KF. Maturation-related changes in the expression of FcgRII and FcgRIII on mouse mast cells with 3T3 fibroblasts stimulates synthesis of globpentaoxylceramide (Forssman glycoplipd) by fibroblasts and surface expression on both populations. J Immunol 140:3090,1988.

65. Katz HR, Raizman MB, Gartner CS, Scott HC, Benson AC, Austen KF. Secretory granule mediator release and generation of oxidative metabolities of arachidonic acid via Fc(R bridging in mouse mast cells. J Immunol 148:868, 1992.

66. Latour S, Bonnerot C, Fridman WH, Daeron M. Induction of TNF-" production by mast cells via Fc(R. J Immunol 149:2155-62, 1992.

67. Daeron M, Bonnerot B, Latour S, Fridman WH. Murine recombinant Fc(RIII but not Fc(RII trigger serotonin release in rat basophilic leukemia cells. J Immunol 149:1365, 1992.

68. Rottem M, Barbieri S, Kinet J-P, Metcalfe DD. Kinetics of the appearance of Fc,RI-bearing cells in interleukin-3-

dependent mouse bone marrow cultures: Correlation with histamine content and mast cell maturation. Blood 79:972-980, 1992.

69. Oettgen HC, Martin TR, Wynshaw-Boris A, Deng C, Drazen JM, Leder P. Active anaphylaxis in IgE-deficient mice. Nature 370:367-370, 1994.

70. Sylvestre DL, Ravetch JV. A dominant role for mast cell Fc Receptors in the Arthus reaction. Immunity 5:387-390, 1996.

71. Huff TF, Lantz CS, Ryan JJ, Leftwich JA. Mast cell committed progenitors. In: Biological and molecular aspects of mast cell and basophil differentiation and function. Kitamura et al. (eds.) New York: Raven Press. 1995, p.105-117.

72. Daeron M, Malbec O, Latour S, Arock M, Fridman WH. Regulation of high- affinity IgE receptor-mediated mast cell activation by murine low- affinity IgG receptors. J Clin Invest 95:577-85, 1995.

73. Scharenberg AM, Kinet JP. The emerging field of receptor-mediated inhibitory signaling : SHP or SHIP? Cell 87:961-64, 1996.

74. Castells M, Katz HR, Austen KF. Molecular and cellular biology of rodent mast cells. Int Arch Allergy Immunol. 99:189-195, 1992.

75. Castells M, Wu S, Arm JP, Austen KF, Katz HR. Cloning of the gp49B gene of the immunoglobulin superfamily and demonstration that one of its two products is an early-expressed mast cell surface protein originally described as gp49. J Biol Chem. 269:8393-8401, 1994.

76. Arm JP, Gurish MF, Reynolds DS, Scott HC, Gartner CS, Austen KF, Katz HR. Molecular cloning of gp49, a cell surface antigen that is preferentially expressed by mouse mast cell progenitors and is a new member of the immunoglobulin superfamily. J Biol Chem 266:15966, 1991.

77. Katz HR, Austen KF. A newly recognized pathway for the negative regulationof mast cell-dependent hypersensitivity and inflammation mediated by an endogenous cell surface receptor of the gp49 family. J Immunol 158:,1997.

78. Katz HR, Vivier E, Castells MC, McCormick M, Chambers JM, Austen FK. PNAS USA 93:10809-12, 1996.

79. Type I Tranmembrane receptor with inhibitory function in mouse mast cells and NK cells. J Immunol 158:, 1997.

80. Arm JP, Nwankwo Ch, Austen FK. Molecular identification of a novel family of human Ig superfamily members that possess immunoreceptor Ytrosine- based inhibition motifs and homology to the mouse gp49B1 inhibitory receptor. J Immunol 15:2342-49, 1997.

81. Franji P, Oskerizian C, Cacaraci F et al. Antigen-dependent stimulation of bone marrow-derived mast cells of MHC class II-restricted T cell hybridoma. J Immunol 151:6318-6328, 1993.

82. Fox CC, Lakshmanan RR. Rat mast cells express accessory molecules for antigen presentation. FASEB Journal 1994, A498 (Abstract).

83. Fuleihan R, Ramesh N, Geha RS. Role of CD40-CD40-ligand interaction in Ig-isotope switching. Current Opin Immunol 5:963-967, 1993.

84. Gascan H, Gauchat J-F, Aversa G, van Vlassalaer P, de Vries JE. Anti-CD40 monoclonal antibodies or CD4- T cell clones and IL-4 induce IgG4 and IgE switching in purified human B cells via different signaling pathways. J Immunol 147:8, 1991.

85. G Gauchat J-F, Henchoz S, Mazzel G, Aubrey J-P, et al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 365:340-343, 1993.

Author Information

Mariana Castells, M.D., PhD.

Asst. Professor, Harvard Medical School